Drugs / BCG Vaccine SSI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02729571 Comparator | Sep 2015 → Sep 2016 | tuberculosis | Biofabri, S.L | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG Vaccine SSI | “Eligible adults were randomly assigned (1:1) to receive either BCG Vaccine SSI (5 × 105 colony forming units [CFU] of Danish strain 1331 in 0·1 mL diluent) or MTBVAC (5 × 105...” PMID 31416768 ↗ Aug 2019 |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02729571 ↗ |